Press releases

The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) to an Extraordinary General Meeting on

Wednesday 23 April 2025 at 10.00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

· Curium International Trading B.V. (“Curium”) and Pentwater Capital Management Europe LLP. (“Pentwater”) commit to subscribing to a minimum of approximately DKK 22.5 million and a maximum of approximately DKK 27.8 million depending on the outcome of the rights issue.
· The participation of Curium further validates Curasight’s technology and approach.
· Proceeds from the rights issue will be used to support Curasight’s strategy of developing its diagnostic platform (uTRACE®) and therapeutic platform (uTREAT®) in parallel. 

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) announces that the Board of Directors has today resolved on its intention to carry out a new issue of shares with pre-emption rights for the Company's existing shareholders (the "Rights Issue"). The Rights Issue is subject to approval at an extraordinary general meeting ("EGM"), authorizing the Board of Directors to carry out the Rights Issue and that the Board subsequently resolves to utilize the authorization to carry out the Rights Issue. If the Rights Issue is fully subscribed, the Company will raise approximately DKK 100 million (before deduction of transaction costs).

Two new shareholders have committed to participate in the rights issue: Curium and Pentwater. Curium, a leader in radiopharmaceuticals and an existing partner to Curasight, has expressed its strong support for the Rights Issue and has committed to subscribe for a total of DKK 17.8 million. Curium’s investment in Curasight serves as a significant endorsement of its groundbreaking uPAR-based technology, which integrates precision diagnostics with targeted therapy to revolutionize cancer treatment. As the global leader in radiopharmaceuticals, Curium brings unparalleled expertise and resources to accelerate Curasight’s development and commercialization efforts. This partnership validates Curasight’s innovative approach, solidifying its position as a leader in the field and paving the way for revolutionary advancements in oncology care worldwide. Pentwater has committed to subscribe for 10 percent of the final issue volume, with a minimum investment of approximately DKK 4.7 million. This marks the first investment for both Curium and Pentwater in Curasight. Additionally, Curasight’s management and members of the Board of Directors have committed to subscribe for a total of approximately DKK 5.2 million. Thus, the total subscription commitments in the Rights Issue amount to approximately DKK 27.7 million, corresponding to approximately 27.7 percent of the Rights Issue. Furthermore, the Company has received guarantee commitments of approximately DKK 19.3 million, corresponding to approximately 19.3 percent of the Rights Issue. In total, the Rights Issue is thus covered to DKK 47 million, which corresponds to approximately 47 percent through subscription and guarantee commitments. The company also announces that the publication of its interim report for the first quarter of 2025 will be brought forward to 25 April 2025, due to the Rights Issue.

To ensure financial flexibility until the completion of the Rights Issue, the Company has raised a bridge loan of DKK 8 million. The Company has also renegotiated and extended its outstanding loan with Fenja Capital II A/S (“Fenja Capital”).

Copenhagen, Denmark, March 26, 2025 – Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) announces that the Company’s Annual General Meeting will be held on May 28, 2025 and an updated financial calendar for rest of 2025.

Business Highlights during the fourth quarter of 2024

· Curasight designates brain cancer as initial indication for uTREAT®
· Data from the Phase II uTRACE® trial in brain cancer patients published in the peer-reviewed journal EJNMMI Research
· Entered into a clinical supply agreement with Curium for Lutethium-177 for uTREAT

Copenhagen, Denmark, 27 February 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the year-end report Q4 2024. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Copenhagen, Denmark, 5 February 2025 - Curasight A/S (“Curasight” or the “Company” - TICKER: CURAS) announces that the Company’s Annual General Meeting will be held on 10 April 2025 and an updated financial calendar for rest of 2025

Copenhagen, Denmark, 10 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the disclosure of participation by members of Curasight’s Board of Directors and Executive Management team in the warrant exercise conducted on December 5[th] 2024.

Copenhagen, Denmark, 10 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces the outcome of the exercise of warrants of series TO2, which were issued in connection with Curasight A/S rights issue and directed issue of units earlier in 2024 (“TO2”). In total, 466,453 warrants of series TO2 were exercised, corresponding to a subscription rate of approximately 12.7 percent. Curasight is thus provided approximately DKK 5.4 million before deduction of transaction related costs.

Copenhagen, Denmark, 2 December 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that SEB reiterates a fair value for Curasight's shares of DKK 54 per share, which implies an upside of 370% from the TO2 warrant strike price of DKK 11.50

The 3[rd] of December 2024 is the last day of trading in warrants of series TO2, which were issued in connection with Curasight A/S ("Curasight" or the "Company") preferential rights issue and directed issue of units in September 2024. The exercise period runs until the 5[th] of December 2024.

· Agreement ensures supply of non-carrier-added Lutetium-177 for uTREAT® development and commercial supply including plans for upcoming pivotal therapy trials
· The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer

Copenhagen, Denmark, November 22 2024 – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announced today that it has entered into a clinical supply agreement with Curium – a global leader in radiopharmaceuticals – for the supply of non-carrier-added Lutetium-177 for Curasight’s uTREAT®.